研修医2年目の八田幸乃先生がFirst authorのCase reportがInternal Medicineにアクセプトされました。

ニボルマブを免疫関連有害事象のため中止しましたが、その後も効果を維持し長期生存されている胃癌症例の報告です。

Case report: A Durable Response after the Discontinuation of Nivolumab in an Advanced Gastric Cancer Patient: A Case Report

Authors: Yukino Yatsuda, MD1, Suguru Hirose, MD1, Yoshimi Ito, MD1, Tsubasa Onoda, MD1, Yutaro Sugiyama, MD1, Miho Nagafuchi, MD1, Hirosumi Suzuki, MD1, Yusuke Niisato, MD1, Yoshitaka Tange, MD1, Takafumi Ikeda, MD1, Takeshi Yamada, MD, PhD1, Yoshiyuki Yamamoto MD, PhD1, Mariko Ohyama Osawa, MD2, Noriaki Sakamoto, MD, PhD3, Toshikazu Moriwaki, MD, PhD1 and Yuji Mizokami, MD, PhD1

Abstract: A durable response after the discontinuation of immune checkpoint–inhibitor therapy has previously been reported in several cancers. We herein describe a patient with gastric cancer who maintained a durable response after the discontinuation of nivolumab. A 65-year-old man was treated with nivolumab as a sixth-line therapy for recurrent gastric cancer. After four cycles of nivolumab therapy, he showed a partial response. But the treatment was discontinued when two immune-related adverse events occurred after six cycles. Disease regression was sustained for approximately 2 years, without the re-administration of nivolumab. The characteristics leading to such responses are unclear, and further studies are warranted in this regard.